Population pharmacokinetics of favipiravir in patients with COVID‐19

• Үндсэн зохиолчид: Kei Irie (Зохиогч), Atsushi Nakagawa (Зохиогч), Hirotoshi Fujita (Зохиогч), Ryo Tamura (Зохиогч), Masaaki Eto (Зохиогч), Hiroaki Ikesue (Зохиогч), Nobuyuki Muroi (Зохиогч), Shoji Fukushima (Зохиогч), Keisuke Tomii (Зохиогч), Tohru Hashida (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Wiley, 2021-10-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Abstract The antiretroviral drug favipiravir (FPV) inhibits RNA‐dependent RNA polymerase. It has been developed for the treatment of the novel coronavirus (severe acute respiratory syndrome coronavirus 2) infection disease, coronavirus disease 2019 (COVID‐19). However, its pharmacokinetics in patien...